Diabetic Macular Oedema, Retina/Vitreous
Read Time: 7 mins

Taking a Clear View – Efficacy and Durability of Aflibercept in Neovascular Age-related Macular Degeneration

Copy Link
Published Online: Nov 23rd 2016 European Ophthalmic Review, 2016;10(Suppl 1):3–10
Authors: Jean-François Korobelnik, Sebastian M Waldstein, Faruque Ghanchi, Sascha Fauser
Quick Links:
Article Information

Aflibercept is effective in preventing progression in neovascular age-related macular degeneration (nAMD) which is the leading cause of vision loss in the elderly. This indication is supported by extensive data from studies such as VIEW 1 and 2 (n=2,457) in which aflibercept showed efficacy across a broad nAMD patient population. These studies have increased knowledge of retinal biomarkers, increased understanding of nAMD and the findings could help inform treatment decisions. Aflibercept, like ranibizumab, requires regular intraocular injections that can negatively impact quality of life. Findings from studies using treat-and-extend regimens indicate that after one years’ treatment, patients can be moved to aflibercept dosing intervals of greater than 8 weeks whilst maintaining efficacy. Emerging real-world data indicate that aflibercept can be given bimonthly (after three initial monthly doses). Recent findings suggest that when VEGF suppression therapy is stopped clinical activity in nAMD resumes sooner than was previously thought. VEGF levels in the retina consequently increase whilst circulating levels may be undetectable. This indicates that more sensitive methods are needed to detect pathologically important levels of VEGF in circulation. Aflibercept is suited to proactive treatment regimens and has a sustained mechanism of action (VEGF suppression time in the aqueous humour of 71 days versus 38 days for ranibizumab) which suggests that the dosing intervals may be further extended after one year. Data from the ongoing ATLAS study show that in treatment-naïve patients, following 1 year of aflibercept, dosing intervals may be extended by 2-week intervals to a maximum 16 weeks. Such reductions in dose frequency have the potential to both reduce the pressure on clinics and improve quality of life for patients with nAMD.


Neovascular age-related macular degeneration, aflibercept


Neovascular age-related macular degeneration (nAMD) is highly prevalent particularly among elderly populations worldwide, and early treatment is imperative to prevent devastating progressive irreversible vision loss and eventual legal blindness.1–3 It is important that patients‘ vision is maintained in nAMD rather than following the deteriorating course that characterises the disease. Several anti-vascular endothelial growth factor (VEGF) medications are available for the treatment of nAMD but these have differing modes of action, allow differing dosing regimens.4,5 This article reports a symposium that aimed to evaluate the use and effectiveness of aflibercept (Eylea® , Bayer, Leverkusen, Germany) in nAMD, broadly across the disease, in patient subtypes and those with disease progression. The possible impact of molecular design of aflibercept on the durability and efficacy of anti-VEGF agents was also explored.

The use of aflibercept in nAMD is supported by two large pivotal trials that showed notable and sustained efficacy.6 These studies have also explored long-term use of aflibercept and its effect on vision outcomes.6–8 More recently, data have been gathered on treat-and-extend regimens and real-world visual acuity outcomes with use of aflibercept.9,10

In nAMD, anti-VEGF treatments are given as intraocular injections which have a high treatment burden and this can negatively impact quality of life.4,11 Aflibercept allows some patients who have completed one year of on-label treatment to be moved to less frequent dosing than every 8 weeks. This does not compromise efficacy which is desirable for both patient and ophthalmologist and has the potential to reduce costs.12 Several ongoing and planned audits aim to provide more real-world evidence of the impact of aflibercept in nAMD and aim to provide data on long term outcomes. These audits also include aflibercept regimens with extended treatment intervals. When complete, the study findings may help to shape future treatment approaches in nAMD.

Strength across the disease – evidence in neovascular age-related macular degeneration
Sebastian M Waldstein
Medical University of Vienna, Austria
nAMD is the leading cause of vision loss in the elderly13 and is a leading cause of legally recognised blindness that affects 10–13% of adults aged >65 years in North America and other genetically similar populations.14 The disease affects a similar proportion of Asian and Caucasian individuals.15–17 The prevalence of nAMD increases exponentially with every decade after the age of 50 years.13 Anti-VEGF agents now provide a highly effective treatment option for nAMD and have lessened the impact of the disease.6,18,19 These treatments, however, have turned the burden of disease in nAMD into a burden of care.14

The efficacy of anti-VEGF treatments in nAMD has been demonstrated in numerous clinical trials, the largest of which were the VIEW studies (VIEW 1 in US, VIEW 2 in Europe, Asia and Australia, total n=2,457 – see end of text for study name definitions).6 Patients were randomised equally to either intravitreal ranibizumab (Lucentis®, Genentech, South San Francisco, California, US) (0.5 mg/4 weeks) or three different intravitreal doses of aflibercept: 2 mg/4 weeks, 0.5 mg/4 weeks (unlicensed dose) or 2 mg/8 weeks after 3 monthly injections. These dosing regimens were maintained for 56 weeks after which both agents were given as needed on a pro re nata (PRN) basis but had to be administered at least quarterly until week 96 with monthly monitoring. It should be noted that the treatment regimen for ranibizumab as used in the VIEW studies did not reflect its current recommended treatment frequency. The licensed posology for ranibizumab states that initially three or more consecutive, monthly injections may be needed but thereafter, monitoring and treatment intervals should be determined by the physician and based on disease activity.20 The licensed posology for aflibercept states that it should be initiated with one injection per month for three consecutive doses, followed by one injection every two months. After the first 12 months the treatment interval may be extended based on visual and/or anatomic outcomes.21

Baseline demographics in the VIEW studies were well balanced in the treatment arms and representative of typical treatment-naïve, nAMD populations in clinical trials.6 For the primary outcome, the proportion of patients maintaining vision (losing <15 ETDRS letters of best corrected visual activity [BCVA]) at week 52 was similar across all treatment arms (95% of patients treated with aflibercept 2 mg/8 weeks versus 94% of patients treated with ranibizumab 0.5 mg/4 weeks).6 At week 96 the proportions maintaining vision were 92% in both groups. In addition, mean reductions in central retinal thickness (CRT) at week 52 were also similar across treatment arms (-139 µm for aflibercept 2 mg/8 weeks versus -128 µm for ranibizumab 0.5 mg/4 weeks. At Week 96, these CRT values were -133 µm and -118 µm, respectively. Fewer injections of aflibercept were administered in the 8-weekly 2 mg aflibercept arm to week 96 compared with ranibizumab (11.2 for aflibercept 2 mg/8 weeks versus 16.5 for ranibizumab 0.5 mg/4 weeks). In both the VIEW 1 and 2 studies, aflibercept had a safety profile similar to that of ranibizumab.

As a result of the VIEW and other anti-VEGF trials, more is known about the pathophysiology of nAMD and imaging biomarkers for disease progression. An example of such a biomarker is pigment epithelial detachment (PED). PED lesions have varying morphology but are important prognostic factors in nAMD patients. Although not primarily associated with vision loss, new onset PEDs are commonly associated with a profound subsequent deterioration in BCVA.22 In patients aged over 55 years, PED lesions often occur secondary to choroidal neovascularization.23 Approximately 50% of patients with newly diagnosed PED experience significant visual loss (>3 lines) one year from diagnosis.24

In the VIEW 2 trial, a reading-centre based grading of monthly optical coherence tomography (OCT) scans was performed. All patients underwent advanced image analysis for the characteristic pathomorphologic lesions in nAMD at all time points. Of the 1,202 patients available for intention-to-treat (ITT) analysis, 64.4% of eyes had intra-retinal cystoid (IRC) fluid, 84.1% had subretinal fluid (SRF) and 80.1% had PED lesions at baseline.14 These features are therefore very common in nAMD and each is diagnostically important. Subanalyses showed that the resolution of IRC and SRF from baseline was more pronounced with aflibercept treatment than ranibizumab. In all study arms these improvements were maintained until 96 weeks. At the end of the loading phase (12 weeks), the proportions of patients with IRC, relative to baseline were reduced by 51.2% with 2 mg aflibercept (pooled) and by 45.7% with ranibizumab, and the proportions of patients with SRF relative to baseline were reduced by 68.3% and 60.8%, respectively. There was also a more pronounced reduction of PED lesions with 2 mg aflibercept than ranibizumab and this was maintained to 96 weeks; however, PED lesions remained present throughout the study in at least 50% of patients regardless of treatment. At the end of the loading phase, relative to baseline, the proportion with PEDs was reduced by 35.6% with aflibercept (pooled) and by 28.5%, with ranibizumab (Figure 1).25

In the VIEW studies, most patients maintained good vision under PRN dosing during the second year of the trials but some experienced a sizable decrease in BCVA.26 Examination of retinal morphology showed that these patients were a defined morphologic subgroup who had PEDs at baseline and developed new IRC during the second year.14 This is likely to be a result of insufficient detection and monitoring of PEDs in patients with nAMD. In the second year patients were moved to treatment on a PRN basis and this reactive strategy may have allowed PEDs to worsen leading to secondary IRC formation and irreversible vision loss.14 PEDs should therefore be carefully monitored and PED growth proactively treated prior to the appearance of IRC and consequent retinal damage.22

PED lesions are relatively resistant to therapy. Treatment with aflibercept in the VIEW studies, showed a good efficacy on these lesions. For PEDs observed at single visits, aflibercept 2 mg/8 weeks produced a 23% relative higher rate of PED flattening compared with ranibizumab 0.5 mg/4 weeks. For PEDs observed at two or more consecutive visits (i.e. sustained PED flattening), aflibercept 2 mg/8 weeks produced a similar rate of sustained PED flattening compared with ranibizumab.27,28

An important putative subtype of nAMD is polypoidal choroidal vasculopathy (PCV). This is characterised by inner choroidal abnormal vascular networks ending in aneurysmal dilatations (polyps).29 PCVs

are most common in Asian communities (Chinese: 22.3–24.5%, Korean: 22.2–24.5%, Japanese: 23.0–54.7%, Taiwanese: 49.0%, Caucasian: 8.0– 13.0%).30 The incidence however, may be underestimated since definitive diagnosis requires indocyanine green angiography (ICGA) and this is not routinely performed in many countries.31 Further work is therefore needed to establish the true prevalence of PCV.

In the VIEW 2 study, a subgroup of 101 Japanese patients were examined using ICGA and 33% were found to have PCV; this was balanced in all four treatment groups. Among these patients, over 96 weeks, the mean change in CRT in all aflibercept-treated groups was similar in patients with or without PCV (Figure 2).32 This indicates the versatility of aflibercept in different types of nAMD but it should be noted that these results are from a small number of patients. In a series of PCV case studies conducted in Japan (n=16–91, total: 336), 33.3–77.7% of aflibercepttreated patients showed complete polyp regression.33–38 The ongoing Aflibercept in Polypoidal Choroidal Vasculopathy (PLANET) study (Phase 4, planned n=313) aims to collect further data from multiple Australian, Asian and European centres on the efficacy and safety of aflibercept with and without photodynamic therapy in subjects with PCV.39

Translating efficacy into real-world effectiveness
Faruque Ghanchi
Bradford Teaching Hospitals, UK
In managing nAMD it is important to strike a balance between under-treatment resulting in poor vision and over-treatment resulting in a high burden on patients and excessive costs. A treatment regimen should enable the physician to monitor, evaluate, and treat at the same time to reduce unnecessary visits. It is thus desirable to reduce the frequency of intraocular injections. For aflibercept, three treatments are initially given at monthly intervals and then the injection interval is extended to every two months for the first year.21 In the second year, the treatment interval can be further extended to 10 weeks and if the anatomic response is maintained it may be further extended to 12 weeks.6,32

In the two pivotal trials of ranibizumab in the treatment of nAMD, ANCHOR and MARINA, (n=423 and 716) injections were given monthly over 12 months, visual acuity improvements of 11.3 and 7.2 letters from baseline were reported.18,19 However, a database study of five years’ clinical experience in 92,976 treatment episodes (n=12,951 eyes of 11,135 patients) at centres in the UK did not find the same level of acuity improvement.40 At week 52 there was a 2-letter improvement in vision but by week 156 this had changed to a 2-letter deterioration compared with baseline suggesting that ranibizumab did not perform as well in real-world use as in clinical trial settings.

The National Aflibercept UK User Group was established to document real-world experience of aflibercept in the management of nAMD at multiple centres. This is an audit conducted at 16 centres using the regimen used in the VIEW studies. The mean patient age was 80.0 years (median: 81.0 years, 63.7% female).41,42 At baseline the mean visual acuity was 53.7; after 1 year (primary outcome) this was 58.8 (5.4 letters gained) after a mean 7.0 injections (Figure 3). Among secondary outcomes, patients with the poorest baseline visual acuity (<35 letters) gained approximately 10 letters by 1 year, a greater improvement than seen in patients with better baseline vision (35 letters – >70 letters) who improved by approximately 5 letters. In addition, the proportion of patients with legal vision for driving (BCVA >70 letters) more than doubled during treatment (17.2% of eyes at baseline increasing to 35.7% of eyes at Month 12). Approximately 92.8% of eyes maintained vision during aflibercept treatment (lost <15 letters) at 1 year,41 a comparable figure to the 95.4% maintaining vision in the bimonthly arm of the VIEW studies. The second year of the aflibercept audit study will include useful outcome data on patients who have moved to treat-and-extend regimens where possible.

Other real-world audits have also shown the rapid and robust effect of aflibercept in nAMD. In a retrospective review of records of 250 treatment-naïve nAMD patients at the Moorfields Eye Hospital, London, UK, patients received monthly injections (loading dose) followed by fixed bimonthly dosing.43 After 16 weeks, the proportion of patients with legal driving vision had more than doubled (13.6% at baseline and 34.4% at 16 weeks) (Figure 4). In addition, there was a mean gain of +7.2 after 8 weeks and +6.6 letters after 16 weeks. The proportion of patients with a CRT <300 µm at baseline increased to 89.6% after 16 weeks; and there was a mean reduction of -76.7 µm after 8 weeks and -70.2 µm after 16 weeks.

A real-world study, the ongoing RAINBOW study, aims to evaluate the use of aflibercept in nAMD in France.9,44 The study has a target of 600 retrospective and prospective treatment-naïve patients, evaluated over a 48-month period after the first aflibercept injection. Interim, 3-month results from 81 patients are positive and show a vision improvement +6.9 ± 12.1 letters BCVA from baseline which is similar to the previous findings of the VIEW 1 and 2 studies.

Data available to date from real-world studies and audits (n=52–790) all show substantial benefits from aflibercept treatment (Table 1) with visual acuity gains of 5.4–8.5 letters over 16 weeks to 1 year and 92.8–96.2% with stable (<15 letter vision loss) over 1 year.6,8,45–47 Further planned or ongoing Phase IV/IIIb trials are expanding the evidence base

for treat-and-extend regimens of aflibercept in nAMD. These include the clinical trials ARIES48 (planned n=268) and AZURE49 (planned n=330).

Other ongoing and forthcoming trials include: TITAN50 (planned n=225 in patients with nAMD and refractory to ranibizumab), PERSEUS51 (planned n=988 patients with nAMD) and PERSEUS-IT52 (planned n=800 treatmentnaïve patients with nAMD).

Emerging real-life evidence therefore indicates that bimonthly aflibercept is an effective treatment option in real-world management of nAMD. This treatment achieves good visual outcomes with reduced treatment burden compared with ranibizumab. The sustained efficacy of aflibercept lends itself to extended treatment intervals, helping to improve patient throughput in the clinic and reduce burden of administering and receiving intraocular injections for both clinicians and patients.

Aflibercept – designed to make a difference
Sascha Fauser
University Hospital of Cologne, Germany
Aflibercept acts by binding to key circulating factors, VEGF-A, VEGF-B and placental growth factor (PlGF) which inhibits binding of VEGF to VEGF receptors (VEGFRs) 1 and 2.53 Various important processes in the maintenance of tissue function in normal and disease conditions are therefore disrupted, including: vascular and non-vascular functions, angiogenesis, vascular permeability and lymphangiogenesis. Aflibercept is a fusion protein consisting of human VEGFR-1 and VEGFR-2 domains and human IgG1 Fc.54,55 It has a dual action and traps all VEGF-A isoforms and PIGF. Aflibercept was designed to block all members of the VEGF family; it binds in a strict 1:1 ratio and has a higher affinity for VEGF than native receptors. As a result of its different binding domains, aflibercept is able to form inert complexes with VEGF.

The pharmacokinetic profile of aflibercept provides sustained efficacy and allows long intervals between doses in many patients. A timeand dose-dependent mathematical model found that the intravitreal biological activity of a 0.5 mg dose of ranibizumab 30 days after injection is equivalent to the predicted activity of a 1.15 mg (unlicensed) dose of aflibercept after 79 days. This was also predicted to be equivalent to the activity of a 4.0 mg (unlicensed) dose of aflibercept after 87 days.56 The intravitreal half-lives of ranibizumab, bevacizumab, and aflibercept were estimated to be 3.2, 5.6, and 4.8 days, respectively.57

A study that included 83 patients with nAMD, showed that ranibizumab 0.5 mg suppressed VEGF in the aqueous humour for a mean 36.4 ± 6.7 days (standard deviation [SD]) following an injection. In individual patients this suppression time was very consistent (intra-individual stability >3 years).58 In addition, there were no rebound effects and

VEGF levels were not associated with choroidal neovascularization. In comparison, a nonrandomised prospective clinical study that included

27 patients treated with aflibercept, given on an unlicensed PRN basis, showed that VEGF in the aqueous humour was suppressed for a mean 71 ± 18 days (SD) (Figure 5).59 This suggested a durable VEGF inhibition for most patients dosed with aflibercept every 8 weeks.

Despite the wide range of VEGF suppression times for anti-VEGF treatments, it is difficult to correlate these with clinical performance. VEGF is necessary but not sufficient for recurrent disease activity. Loss of VEGF suppression does not result in the immediate appearance of morphological or functional signs. Furthermore, studies which typically treat at 4-week intervals also level out some differences between anti-VEGF agents.60,61

There are limited data on the sustained effect of less frequent dosing of anti-VEGF treatments in nAMD. In the VIEW studies patients who received bimonthly or quarterly aflibercept dosing from week 52 to 96 showed good maintenance of visual acuity (losing <15 ETDRS letters).6,8 During the second year of the VIEW 1 study (weeks 52–96) and its extension (weeks 96–192), approximately half of the patients were maintained on quarterly aflibercept dosing over a total of 3 years.7 During this time, mean BCVA was essentially stable, changing only from 66.0 to 62.5 letters (+10.4 to +7.0 letters compared with baseline) (Figure 6).

In the LUCAS study that compared ranibizumab with bevacizumab (n=431), patients were initially treated on a monthly basis and then the dosing intervals were extended as needed by 2-week increments up to 12 weeks.62 In order to maintain visual acuity, 37.1% of patients receiving ranibizumab could not be extended beyond 12-week intervals, 4.7% could not be extended beyond 8 week intervals and 32.9% could not be extended beyond 6 week intervals. The mean treatment interval for ranibizumab over 1 year was 6 weeks. Similar dosing intervals were necessary with bevacizumab.

The treat-and-extend regimen of aflibercept is being further investigated in the ongoing ATLAS study. This is a prospective, 2-year clinical trial in 40 patients with treatment-naïve nAMD in which, following one year of on-label treatment, dosing intervals are extended by 2-week increments up to a maximum 16 weeks provided that visual acuity is maintained and extension criteria are met. Results at 1 year showed that less frequent dosing was possible in most patients and efficacy was sustained.10 For the primary outcome, there was a mean gain of 7.5 letters (ITT population). For other outcomes, the mean number of injections during the year was 8 and over 70% of patients achieved a treatment interval of =8 weeks. Results for these endpoints at 2 years are awaited.

Discussion and conclusion
In the treatment of nAMD, aflibercept can be differentiated from other anti-VEGF agents on the basis of its innovative molecular design, which results in a robust and broad mechanism of action59,63 and provides sustained action.6,7 In a series of large clinical trials aflibercept showed favourable efficacy and this experience has been continued in completed and ongoing audits and studies of real-world clinical practice.41,45,46

In treating nAMD with anti-VEGF agents, frequent intraocular injections create a high treatment burden both for patients and ophthalmologists. Some physicians believe that using a PRN regimen when treating nAMD can expose patients to multiple disease recurrences, resulting in disease progression. Providing regular treatments at extended intervals appears to be a more advantageous route to controlling the disease. For many patients, after the initial loading doses, extending dose intervals to 8 or 12 weeks provides sustained maintenance of vision for durations up to 2 years6,32 and possibly beyond. Some ophthalmologists have suggested that treatment cessation in certain patients may be possible but identifying suitable patients is challenging.

The finding that clinical activity in nAMD returns at around half the duration of VEGF suppression may indicate that current assay methods are insufficiently sensitive to detect the low levels of VEGF that are needed to reactivate the pathological processes. It may also indicate that circulating levels of VEGF are lower or rise more slowly than those in the retina so detecting zero levels in the aqueous humour does not indicate an absence of disease activity and progression.

Collective clinical experience to date, shows that aflibercept can be used as a proactive, effective and durable treatment option in all different forms of nAMD, including patients with disease progression. Further post-marketing and real-world audits that aim to evaluate aflibercept in nAMD are in progress. These are likely to create a substantial body of evidence supporting its wider use in the maintenance of vision with minimal dosing. As the leading cause of blindness in the elderly, it is imperative that nAMD is treated in as many patients as possible. The efficacy of anti-VEGF agents and their use in extended treatment regimens may help achieve that goal.

Definitions of study name abbreviations:
ANCHOR: Antibody for the treatment of predominantly classic choroidal neovascularization in AMD; ARIES: Managing age-related macular degeneration (nAMD) over 2 years with a treat and extend (T&E) regimen of 2 mg intravetreal aflibercept – a randomized, open-label, activecontrolled, parallel-group Phase IV/IIIb Study; ATLAS: Repeated eye Injections of aflibercept for treatment of wet age related macular degeneration; AZURE: An open-label , randomized, active controlled, parallel-group, Phase 3b study of the efficacy, safety, and tolerability of 2 mg aflibercept administered by intravitreal injections using two different treatment regimens to subjects with neovascular age-related macular degeneration (mAMD); LUCAS: Lucentis compared to avastin study; MARINA: Minimally classic/occult trial of the anti-VEGF antibody ranibizumab in the treatment of neovascular AMD; PERSEUS: Investigating the effectiveness of Eylea in pateints with wet age-related macular degeneration; PERSEUS-IT: Aflibercept (Eylea) in routine clinical practice in patients with age-related macular degeneration in Italy; RAINBOW: Real life of aflibercept In France: observational study in wet AMD; TITAN: Real life of Aflibercept in France in patients refractory to ranibizumab: observational study in wet AMD; VIEW 1 and 2: VEGF Trap-eye: Investigation of efficacy and safety in wet AMD studies.

Article Information:

Sebastian M Waldstein has served as a consultant to Bayer and Novartis Pharma AG. Sascha Fauser has served as a consultant to Bayer, Novartis, Roche and Quantel. Jean-François Korobelnik and Faruque Ghanchi have nothing to disclose in relation to this article. This article has been produced on behalf of Bayer Healthcare and reports on a Bayer funded and organised symposium. This article reports the proceedings of a sponsored satellite symposium held at the EURETINA Congress 2015 and, as such, has not been subject to this journal’s usual peerreview process. The report was reviewed for scientific accuracy by the symposium speakers before publication
Published Online: 3 October 2016


Jean-François Korobelnik, Department of Ophthalmology, CHU de Bordeaux, Hopital Pellegrin, Place Amélie Raba Léon, 33000 Bordeaux, France. E:


The publication of this article was supported by Bayer. The views and opinions expressed are those of the authors and not necessarily those of Bayer


This article is published under the Creative Commons Attribution Noncommercial License, which permits any non-commercial use, distribution, adaptation and reproduction provided the original author(s) and source are given appropriate credit.


Editorial assistance was provided by James Gilbart at Touch Medical Media and funded by Bayer




*EYLEA® (aflibercept solution for injection). Prescribing information can be found below the references.

The publication of this article was supported by Bayer Healthcare. This supplement has been developed by Bayer.

1. Congdon N, O’Colmain B, Klaver CC, et al., Causes and prevalence of visual impairment among adults in the United States, Arch Ophthalmol, 2004;122:477–85.
2. Dixon JA, Oliver SC, Olson JL, et al., VEGF Trap-Eye for the treatment of neovascular age-related macular degeneration, Expert Opin Investig Drugs, 2009;18:1573–80.
3. Stewart MW, Individualized Treatment of Neovascular Age- Related Macular Degeneration: What are Patients Gaining? Or Losing?, J Clin Med, 2015;4:1079–101.
4. Holz FG, Schmitz-Valckenberg S, Fleckenstein M, Recent developments in the treatment of age-related macular degeneration, J Clin Invest, 2014;124:1430–8.
5. Yonekawa Y, Kim IK, Clinical characteristics and current treatment of age-related macular degeneration, Cold Spring Harb Perspect Med, 2015;5:a017178.
6. Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, et al., Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies, Ophthalmology, 2014;121:193–201.
7. Clark WL, Long-term safety of intravitrealaflibercept injection in neovascular AMD, Presented at: America Academy of Ophthalmology, New Orleans, Louisiana, US, November 18, 2013.
8. Heier JS, Brown DM, Chong V, et al., Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration, Ophthalmology, 2012;119:2537–48.
9. Cohen SY, Garcher CP, Korobelnik J-F, et al., Real Life of Aflibercept In FraNce: oBservatiOnal study in Wet AMD: the RAINBOW study. Investigative Ophthalmology & Visual Science, 2015,56:4601.
10. DeCroos F, Prospective, Multicenter Investigation of Aflibercept Treat and Extend Therapy for Neovascular Age-Related Macular Degeneration, Presented at: American Society of Retina Specialists 33rd Annual Meeting, Vienna, Austria, 13 July 2015.
11. Slakter JS, Stur M, Quality of life in patients with age-related macular degeneration: impact of the condition and benefits of treatment, Surv Ophthalmol, 2005;50:263–73.
12. Verner-Cole EA, Davis SJ, Lauer AK, Aflibercept for the treatment of neovascular age-related macular degeneration, Drugs Today (Barc), 2012;48:317–29.
13. Ishikawa M, Jin D, Sawada Y, et al., Future therapies of wet agerelated macular degeneration, J Ophthalmol, 2015;2015:138070.
14. Schmidt-Erfurth U, Waldstein SM, Deak GG, et al., Pigment epithelial detachment followed by retinal cystoid degeneration leads to vision loss in treatment of neovascular age-related macular degeneration, Ophthalmology, 2015;122:822–32.
15. Cheung CM, Tai ES, Kawasaki R, et al., Prevalence of and risk factors for age-related macular degeneration in a multiethnic Asian cohort, Arch Ophthalmol, 2012;130:480–6.
16. Kawasaki R, Wang JJ, Aung T, et al., Prevalence of age-related macular degeneration in a Malay population: the Singapore Malay Eye Study, Ophthalmology, 2008;115:1735–41.
17. Kawasaki R, Yasuda M, Song SJ, et al., The prevalence of agerelated macular degeneration in Asians: a systematic review and meta-analysis, Ophthalmology, 2010;117:921–7.
18. Brown DM, Kaiser PK, Michels M, et al., Ranibizumab versus verteporfin for neovascular age-related macular degeneration, N Engl J Med, 2006;355:1432–44.
19. Rosenfeld PJ, Brown DM, Heier JS, et al., Ranibizumab for neovascular age-related macular degeneration, N Engl J Med, 2006;355:1419–31.
20. Novartis Pharmaceuticals, Lucentis 10 mg/ml solution for injection - Summary of product characteristics, 2014. Available at: (accessed date: 11 November 2015).
21. Bayer PLC, Eylea 40 mg/ml solution for injection in a vial - summary of product characteristics, 2015. Available at: www. (accessed date:2 November 2015).
22. Schmidt-Erfurth U, Waldstein SM, A paradigm shift in imaging biomarkers in neovascular age-related macular degeneration, Prog Retin Eye Res, 2016;50:1–24.
23. Bruce A, O’Day J, McKay D, et al., Retinal pigment epithelial detachment - Pigment epithelial detachment (PED), Optician, 2008;51 wp-content/uploads/importedimages/az120.pdf: (accessed date: 30 October 2015).
24. Todorich B, Pepple K, Mruthyunjaya P, Treatment of Pigment Epithelial Detachments in Age-related Macular Degeneration A significant cause of visual morbidity in neovascular AMD, PEDs remain a treatment challenge, Retinal Physician, 2012;9:30–7.
25. Waldstein SM, Simader C, Staurenghi G, et al., Morphological and functional efficacy of aflibercept and ranibizumab in neovascular age-related macular degeneration, Ophthalmology, 2016;123:1521-9.
26. Richard G, Mones J, Wolf S, et al., Scheduled versus Pro Re Nata Dosing in the VIEW Trials, Ophthalmology, 2015;122:2497–503.
27. Kitchens JW, VEGF Trap-Eye (VIEW) Sub-analysis: Influence of Anatomic Characteristics on Outcomes, Presented at: American Academy of Ophthalmology (AAO) Annual Meeting, New Orleans, Louisiana, USA, 15 November 2013.
28. Shah CP, Anti-VEGF Effect in Eyes With Retinal Pigment Epithelium Elevation in the VIEW 1 and VIEW 2 Studies of Wet AMD Patients - Presentation PA088, Presented at: American Academy of Ophthalmology (AAO) Annual Meeting, New Orleans, Louisiana, USA, 19 November 2013.
29. Laude A, Cackett PD, Vithana EN, et al., Polypoidal choroidal vasculopathy and neovascular age-related macular degeneration: same or different disease?, Prog Retin Eye Res, 2010;29:19–29.
30. Honda S, Matsumiya W, Negi A, Polypoidal choroidal vasculopathy: clinical features and genetic predisposition, Ophthalmologica, 2014;231:59–74.
31. Lee WK, Treatment of polypoidal choroidal vasculopathy, Retina Today, 2012. Available at: treatment-of-polypoidal-choroidal-vasculopathy/ (accessed date 21 June 2016).
32. Ogura Y, VIEW 2 study PCV subanalysis - Effect of EYLEA® on polypoidal choroidal vasculopathy (PCV) - ICGA subanalysis, Presented at: 53rd Annual Meeting of the Japanese Retina and Vitreous Society, Osaka, Japan, November 28–30 2014.
33. Hosokawa M, Shiraga F, Yamashita A, et al., Six-month results of intravitreal aflibercept injections for patients with polypoidal choroidal vasculopathy, Br J Ophthalmol, 2015;99:1087–91.
34. Ijiri S, Sugiyama K, Short-term efficacy of intravitreal aflibercept for patients with treatment-naive polypoidal choroidal vasculopathy, Graefes Arch Clin Exp Ophthalmol, 2015;253:351–7.
35. Inoue M, Arakawa A, Yamane S, et al., Short-term efficacy of intravitreal aflibercept in treatment-naive patients with polypoidal choroidal vasculopathy, Retina, 2014;34:2178–84.
36. Koh A, Lee WK, Chen LJ, et al., EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy, Retina, 2012;32:1453–64.
37. Oishi A, Tsujikawa A, Yamashiro K, et al., One-year result of aflibercept treatment on age-related macular degeneration and predictive factors for visual outcome, Am J Ophthalmol, 2015;159:853–60 e1.
38. Yamamoto A, Okada AA, Kano M, et al., One-Year Results of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy, Ophthalmology, 2015;122:1866–72.
39. (U.S. National Institutes of Health), Aflibercept in Polypoidal Choroidal Vasculopathy (PLANET) NCT02120950, 2014. Available at: CT02120950?term=PLANET+AND+aflibercept&rank=1&show_ locs=Y#locn (accessed date: 2 November 2015).
40. Writing Committee for the UKA-RMDEMRUG, The neovascular age-related macular degeneration database: multicenter study of 92 976 ranibizumab injections: report 1: visual acuity, Ophthalmology, 2014;121:1092–101.
41. Ghanchi F, Aflibercept in the real world setting: Outcomes from UK hospitals, Presented at: The 6th World Congress on Controversies on Ophthalmology, Serrento, italy, 27 March 2015.
42. Talks J, Real world outcome of providing aflibercept according to the VIEW protocol for AMD (127), Presented at: Royal College of Ophthalmologists Annual Congress, Liverpool, 21 May 2015.
43. Sivaprasad S, 2015, Royal College of Ophthalmologists Annual Congress, Liverpool, May 19–21, 2015, 11.55-12.20
44. National Intitutes of Medicine, Real Life of Aflibercept In FraNce: oBservatiOnnal Study in Wet AMD (RAINBOW), 2014. Available at: show/NCT02279537. (date accessed 3 November 2015).
45. Crosby-Nwaobi RR, Hykin PG, Sivaprasad S, Real-world rapid mean visual acuity improvement in patients initiated on aflibercept therapy for treatment-naïve neovascular agerelated macular degeneration (nAMD) Program Number: 4605 Poster Board Number: B0246, Presented at: The Association for Research in Vision and Ophthalmology, Denver, CO, USA, 2015 (date accessed: 20 June 2016)
46. Talks J. Real world data in wet AMD: The National Aflibercept Audit .European Society of Ophthalmology (SOE) Congress, Vienna, Austria 6–9 June 2015.
47. Vazquez-Alfageme C, Patel PJ, Hamilton R, Efficacy of Aflibercept in Treatment-naïve Neovascular Agerelated Macular Degeneration: One-Year Real World Outcomes Program Number: 4613 Poster Board Number: B0254, Association for Research in Vision and Ophthalmology, Denver, Colorado, USA, 6 May 2015.
48. National Institues of Health, Managing Neovascular (Known as “Wet”) Age-related Macular Degeneration Over 2 Years Using Different Treatment Schedules of 2 mg Intravitreal Aflibercept Injected in the Eye NCT02581891, 2015. Available at: show/NCT02581891?term=ARIES+AND+aflibercept&rank=1 (accessed date: 3 November 2015).
49. EU Clinical Trials Register, An open-label, randomized, activecontrolled, parallel-group, Phase-3b study of the efficacy, safety, and tolerability of 2 mg aflibercept administered by intravitreal injections using two different treatment regimens to subjects with neovascular age-related macular degeneration (nAMD). 2013-000120-33, 2015. Available at: (accessed date: 3 November 2015).
50. National Institutes of Health, Real Life of Aflibercept in France in Patients Refractory to Ranibizumab: Observational Study in Wet AMD (TITAN) NCT02321241, 2014. Available at NCT02321241?term=NCT02321241&rank=1 (accessed date: 3 November 2015).
51. National Institutes of Health, Investigating the Effectiveness of Eylea in Patients With Wet Agerelated Macular Degeneration (PERSEUS) NCT01914380, 2013. Available at: NCT01914380?term=NCT01914380.&rank=1 (accessed date: 3 November 2015).
52. National Institutes of Health, Aflibercept (Eylea) in roUtine Clinical Practice in patientS With Wet Age-related Macular Degeneration in Italy (PERSEUS-IT) NCT02289924, 2014. Available at: NCT02289924?term=NCT02289924&rank=1 (accessed date: 3 November 2015).
53. Cao Y, Positive and negative modulation of angiogenesis by VEGFR1 ligands, Sci Signal, 2009;2:re1.
54. Heier JS, VEGF Trap-Eye for Exudative AMD, Retinal Physician, 2009. Available at: aspx?articleid=102898 (date accessed: 20 June 2016).
55. Holash J, Davis S, Papadopoulos N, et al., VEGF-Trap: a VEGF blocker with potent antitumor effects, Proc Natl Acad Sci USA, 2002;99:11393-8.
56. Stewart MW, Rosenfeld PJ, Predicted biological activity of intravitreal VEGF Trap, Br J Ophthalmol, 2008;92:667–8.
57. Stewart MW, Rosenfeld PJ, Penha FM, et al., Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye), Retina, 2012;32:434–57.
58. Muether PS, Hermann MM, Droge K, et al., Long-term stability of vascular endothelial growth factor suppression time under ranibizumab treatment in age-related macular degeneration, Am J Ophthalmol, 2013;156:989–93 e2.
59. 59. Fauser S, Schwabecker V, Muether PS, Suppression of intraocular vascular endothelial growth factor during aflibercept treatment of age-related macular degeneration, Am J Ophthalmol, 2014;158:532–6.
60. Ba J, Peng RS, Xu D, et al., Intravitreal anti-VEGF injections for treating wet age-related macular degeneration: a systematic review and meta-analysis, Drug Des Devel Ther, 2015;9:5397–405.
61. Droege KM, Caramoy A, Kersten A, et al., Patient preference of ranibizumab treatment regimen for neovascular age-related macular degeneration - monthly injections versus pro re nata, Graefes Arch Clin Exp Ophthalmol, 2014;252:31–4.
62. Berg K, Pedersen TR, Sandvik L, et al., Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol, Ophthalmology, 2015;122:146–52.
63. Papadopoulos N, Martin J, Ruan Q, et al., Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab, Angiogenesis, 2012;15:171–85.

Eylea® 40 mg/ml solution for injection in a vial (aflibercept) Prescribing Information
(Refer to full Summary of Product Characteristics (SmPC) before prescribing)

Presentation: 1 ml solution for injection contains 40 mg aflibercept. Each vial contains 100 microlitres, equivalent to 4 mg aflibercept. Indication(s): Treatment of neovascular (wet) age-related macular degeneration (AMD), macular oedema secondary to retinal vein occlusion (branch RVO or central RVO), visual impairment due to diabetic macular oedema (DMO) in adults and visual impairment due to myopic choroidal neovascularisation (myopic CNV). Posology & method of administration: For intravitreal injection only. Must be administered according to medical standards and applicable guidelines by a qualified physician experienced in administering intravitreal injections. Each vial should only be used for the treatment of a single eye. The vial contains more than the recommended dose of 2 mg. The extractable volume of the vial (100 microlitres) is not to be used in total. The excess volume should be expelled before injecting. Refer to SmPC for full details. Adults: The recommended dose is 2 mg aflibercept, equivalent to 50 microlitres. For wAMD treatment is initiated with one injection per month for three consecutive doses, followed by one injection every two months. No requirement for monitoring between injections. After the first 12 months of treatment, and based on visual and/or anatomic outcomes, the treatment interval may be extended such as with a treat-and-extend dosing regimen, where the treatment intervals are gradually increased to maintain stable visual and/or anatomic outcomes; however there are insufficient data to conclude on the length of these intervals. If visual and/ or anatomic outcomes deteriorate, the treatment interval should be shortened accordingly. The schedule for monitoring should therefore be determined by treating physician and may be more frequent than the schedule of injections. For RVO (branch RVO or central RVO), after the initial injection, treatment is given monthly at intervals not shorter than one month. Discontinue if visual and anatomic outcomes indicate that the patient is not benefiting from continued treatment. Treat monthly until maximum visual acuity and/or no signs of disease activity. Three or more consecutive, monthly injections may be needed. Treatment may then be continued with a treat and extend regimen with gradually increased treatment intervals to maintain stable visual and/or anatomic outcomes, however there are insufficient data to conclude on the length of these intervals. Shorten treatment intervals if visual and/or anatomic outcomes deteriorate. The monitoring and treatment schedule should be determined by the treating physician based on the individual patient’s response. For DMO, initiate treatment with one injection/month for 5 consecutive doses, followed by one injection every two months. No requirement for monitoring between injections. After the first 12 months of treatment, and based on visual and/or anatomic outcomes, the treatment interval may be extended such as with a treat-and-extend dosing regimen, where the treatment intervals are gradually increased to maintain stable visual and/or anatomic outcomes; however there are insufficient data to conclude on the length of these intervals. If visual and/ or anatomic outcomes deteriorate, the treatment interval should be shortened accordingly. The schedule for monitoring should therefore be determined by the treating physician and may be more frequent than the schedule of injections. If visual and anatomic outcomes indicate that the patient is not benefiting from continued treatment, treatment should be discontinued. For myopic CNV, a single injection is to be administered. Additional doses may be administered if visual and/or anatomic outcomes indicate that the disease persists. Recurrences should be treated as a new manifestation of the disease. The schedule for monitoring should be determined by the treating physician. The interval between two doses should not be shorter than one month. Hepatic and/or renal impairment: No specific studies have been conducted. Available data do not suggest a need for a dose adjustment. Elderly population: No special considerations are needed. Limited experience in those with DMO over 75 years old. Paediatric population: No data available. Contraindications: Hypersensitivity to active substance or any excipient; active or suspected ocular or periocular infection; active severe intraocular inflammation. Warnings & precautions: As with other intravitreal therapies endophthalmitis has been reported. Aseptic injection technique essential. Patients should be monitored during the week following the injection to permit early treatment if an infection occurs. Patients must report any symptoms of endophthalmitis without delay. Increases in intraocular pressure have been seen within 60 minutes of intravitreal injection; special precaution is needed in patients with poorly controlled glaucoma (do not inject while the intraocular pressure is ≥ 30 mmHg). Immediately after injection, monitor intraocular pressure and perfusion of optic nerve head and manage appropriately. There is a potential for immunogenicity as with other therapeutic proteins; patients should report any signs or symptoms of intraocular inflammation e.g pain, photophobia or redness, which may be a clinical sign of hypersensitivity. Systemic adverse events including non-ocular haemorrhages and arterial thromboembolic events have been reported following intravitreal injection of VEGF inhibitors. Safety and efficacy of concurrent use in both eyes have not been systemically studied. No data is available on concomitant use of Eylea with other anti- VEGF medicinal products (systemic or ocular). Caution in patients with risk factors for development of retinal pigment epithelial tears including large and/or high pigment epithelial retinal detachment. Withhold treatment in patients with: rhegmatogenous retinal detachment or stage 3 or 4 macular holes; with retinal break and do not resume treatment until the break is adequately repaired. Withhold treatment and do not resume before next scheduled treatment if there is: decrease in best-corrected visual acuity of ≥30 letters compared with the last assessment; central foveal subretinal haemorrhage, or haemorrhage ≥50%, of total lesion area. Do not treat in the 28 days prior to or following performed or planned intraocular surgery. Eylea should not be used in pregnancy unless the potential benefit outweighs the potential risk to the foetus. Women of childbearing potential have to use effective contraception during treatment and for at least 3 months after the last intravitreal injection. Populations with limited data: There is limited experience of treatment with Eylea in patients with ischaemic, chronic RVO. In patients presenting with clinical signs of irreversible ischaemic visual function loss, aflibercept treatment is not recommended. There is limited experience in DMO due to type I diabetes or in diabetic patients with an HbA1c over 12% or with proliferative diabetic retinopathy. Eylea has not been studied in patients with active systemic infections, concurrent eye conditions such as retinal detachment or macular hole, or in diabetic patients with uncontrolled hypertension. This lack of information should be considered when treating such patients. In myopic CNV there is no experience with Eylea in the treatment of non-Asian patients, patients who have previously undergone treatment for myopic CNV, and patients with extrafoveal lesions. Interactions: No available data. Fertility, pregnancy & lactation: Not recommended during pregnancy unless potential benefit outweighs potential risk to the foetus. No data available in pregnant women. Studies in animals have shown embryo-foetal toxicity. Women of childbearing potential have to use effective contraception during treatment and for at least 3 months after the last injection. Not recommended during breastfeeding. Excretion in human milk: unknown. Male and female fertility impairment seen in animal studies with high systemic exposure not expected after ocular administration with very low systemic exposure. Effects on ability to drive and use machines: Possible temporary visual disturbances. Patients should not drive or use machines if vision inadequate. Undesirable effects: Very common: Visual acuity reduced, conjunctival haemorrhage (phase III studies: increased incidence in patients receiving antithrombotic agents), eye pain. Common: retinal pigment epithelial tear, detachment of the retinal pigment epithelium, retinal degeneration, vitreous haemorrhage, cataract (nuclear or subcapsular), corneal abrasion or erosion, increased intraocular pressure, blurred vision, vitreous floaters, vitreous detachment, injection site pain, foreign body sensation in eyes, increased lacrimation, eyelid oedema, injection site haemorrhage, punctate keratitis, conjunctival or ocular hyperaemia. Serious: cf. CI/W&P - in addition: blindness, endophthalmitis, cataract traumatic, transient increased intraocular pressure, vitreous detachment, retinal detachment or tear, hypersensitivity (during the post-marketing period, reports of hypersensitivity included rash, pruritus, urticaria, and isolated cases of severe anaphylactic/anaphylactoid reactions), vitreous haemorrhage, cortical cataract, lenticular opacities, corneal epithelium defect/erosion, vitritis, uveitis, iritis, iridocyclitis, anterior chamber flare, arterial thromboembolic events (ATEs) are adverse events potentially related to systemic VEGF inhibition. There is a theoretical risk of arterial thromboembolic events, including stroke and myocardial infarction, following intravitreal use of VEGF inhibitors. Consult the SmPC in relation to other side effects. Overdose: Monitor intraocular pressure and treat if required. Incompatibilities: Do not mix with other medicinal products. Special Precautions for Storage: Store in a refrigerator (2°C to 8°C). Do not freeze. Unopened vials may be kept at room temperature (below 25°C) for up to 24 hours before use. Legal Category: POM. Package Quantities & Basic NHS Costs: Single vial pack £816.00. MA Number(s): EU/1/12/797/002. Further information available from: Bayer plc, Bayer House, Strawberry Hill, Newbury, Berkshire RG14 1JA, United Kingdom. Telephone: 01635 563000. Date of preparation: September 2016

Eylea® is a trademark of the Bayer Group

Adverse events should be reported. Reporting forms and information can be found at www. Adverse events should also be reported to Bayer plc. Tel.: 01635 563500, Fax.: 01635 563703, Email:

Further Resources

Share this Article
Related Content In Retina/Vitreous
  • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72